Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION)
Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION)
复制标题
DOI：
10.1182/blood-2013-06-511592
复制
发表时间：
2014-01-23
期刊：
影响因子：
20.3
通讯作者：
Hochhaus, Andreas
中科院分区：
文献类型：
--
作者：
Jabbour, Elias;Kantarjian, Hagop M.;Hochhaus, Andreas
这项分析探讨了在达沙替尼与伊马替尼的3期试验中，早期细胞遗传学和分子反应对慢性粒细胞白血病慢性期(CML-CP)患者预后的影响。新诊断的CML-CP患者被随机分为达沙替尼100 mg(n=259)和伊马替尼400 mg(n=260)，每日1次。回溯性里程碑分析包括在相关时间点(3、6或12个月)可评估的患者。达沙替尼与伊马替尼相比，完成细胞遗传学反应的中位时间分别为3个月和6个月。在3个月和6个月时，bcr-abl转录本水平的患者比例
This analysis explores the impact of early cytogenetic and molecular responses on the outcomes of patients with chronic myeloid leukemia in chronic phase (CML-CP) in the phase 3 DASatinib versus Imatinib Study In treatment-Naive CML patients trial with a minimum follow-up of 3 years. Patients with newly diagnosed CML-CP were randomized to receive 100 mg dasatinib (n = 259) or 400 mg imatinib (n = 260) once daily. The retrospective landmark analysis included patients evaluable at the relevant timepoint (3, 6, or 12 months). Median time to complete cytogenetic response was 3 vs 6 months with dasatinib vs imatinib. At 3 and 6 months, the proportion of patients with BCR-ABL transcript levels